Juul Labs today announced findings from its science and research program at the 2021 Annual Meeting of the Society for Research on Nicotine & Tobacco (SRNT), which was held virtually. The studies presented covered a wide range of topics that contribute to the growing body of scientific evidence on ENDS products, including information about their harm reduction potential as well as rates of complete switching to ENDS among adult smokers.
Below is the full list of studies presented by Juul Labs:
In addition to the nine posters presented by Juul Labs, consultants to Juul Labs (Pinney Associates) and an independent contract research organization (Centre for Substance Use Research) presented two studies sponsored by Juul Labs:
To better understand patterns of tobacco product use among adult smokers, Juul Labs has developed an extensive behavioral research program that includes measurements of complete switching from combustible cigarettes to the JUUL System among adult smokers. Among the data presented at SRNT are the results of a longitudinal study which found that more than 50% of adult smokers who purchased the JUUL System reported complete switching at a 12-month follow-up assessment. Complete switching was defined as no cigarette smoking in the past 30 days — not even a puff.
Another new study presented this week examined trends in dual use of the JUUL System and cigarettes among adult smokers who recently purchased JUUL products, as well as any changes in cigarette consumption among these dual-users. While dual use of JUUL products and cigarettes was initially high, it declined over time, and the majority of adult smokers who began by dual-using ultimately switched completely away from cigarettes 12 months after initial purchase. Additionally, over 60% of dual-users at 12 months substantially reduced their average daily cigarette consumption. Researchers concluded that dual use is often a transitional stage characterized by reductions in cigarette consumption followed by complete switching away from cigarettes.
Juul Labs is fully committed to the Premarket Tobacco Product Application (PMTA) process in the United States, and to that end has built a robust scientific research program to help assess the harm reduction potential of JUUL products, including their impact on the individual user, their ability to move adult smokers away from combustible cigarettes, and the net-population impact on public health.
We are committed to working cooperatively with regulators, public health officials, and other stakeholders to preserve the historic opportunity to transition adult smokers away from combustible cigarettes, while combating underage use.
We will continue to share results from our science and research program transparently as we work to support the scientific basis for the category.
About Juul Labs
Juul Labs’ mission is to transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products. We believe that vapor products can offer adult smokers an alternative to combustible cigarettes and, in so doing, reduce the harm associated with tobacco. Nicotine is addictive and can cause certain harms to health. It would be best if no one used any nicotine product. Anyone who smokes should quit. Adult smokers who have not successfully quit should completely switch to potentially less harmful alternative nicotine products. Juul Labs does not want any non-nicotine users, especially those underage, to try our products, as they exist only to transition adult smokers away from combustible cigarettes. JUUL products are not intended to be used for smoking cessation or other therapeutic purposes.
For the general public and policymakers looking for more information about the company, please visit www.juullabs.com.
For scientists, members of the public health community, regulators and policymakers looking to learn more about Juul Labs’ scientific research, please visit www.juullabsscience.com.